Eosinofilia

1. Sakula A. Charcot-Leyden crystals and Curschmann spirals in asthmatic sputum. Thorax 1986;41(7):503–7.

2. Davoine F, Lacy P. Eosinophil cytokines, chemokines, and growth factors: emerging roles in immunity. Front Immunol 2014;5:570

3. Melo RCN, Weller PF. Unraveling the complexity of lipid body organelles in human eosinophils. J Leukoc Biol 2014;96(5):703–12.

4. Spencer LA, Bonjour K, Melo RCN, et al. Eosinophil secretion of granule-derived cytokines. Front Immunol 2014;5:496.

5. Ueki S, Tokunaga T, Melo RCN, et al. Charcot-Leyden crystal formation is closely associated with eosinophil extracellular trap cell death. Blood 2018;132(20):2183–7.

6. Sher A, Butterworth AE, Colley DG, et al. Immune responses during human schistosomiasis mansoni. II. Occurrence of eosinophil-dependent cytotoxic antibodies in relation to intensity and duration of infection. Am J Trop Med Hyg 1977;26(5 Pt1):909–16.

7. Moser G, Sher A. Studies of the antibody-dependent killing of schistosomula of Schistosoma mansoni employing haptenic target antigens. II. In vitro killing of TNP-schistosomula by human eosinophils and neutrophils. J Immunol 1981;126(3):1025–9.

8. Lee JJ, Rosenberg HF, editors. Eosinophils in health and disease. Elsevier; 2012. 9. Weller PF, Spencer LA. Functions of tissue-resident eosinophils. Nat Rev Immunol 2017;17(12):746–60.

10. Hilderink JM, Klinkenberg LJJ, Aakre KM, et al. Within-day biological variation and hour-to-hour reference change values for hematological parameters. Clin Chem Lab Med 2017;55(7):1013–24.

11. Sennels HP, Jørgensen HL, Hansen A-LS, et al. Diurnal variation of hematology parameters in healthy young males: the Bispebjerg study of diurnal variations. Scand J Clin Lab Invest 2011;71(7):532–41.

12. Chen Y-YK, Khoury P, Ware JM, et al. Marked and persistent eosinophilia in the absence of clinical manifestations. J Allergy Clin Immunol 2014;133(4):1195–202.

13. Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 2007;133(4):1342–63.

14. Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011;128(1):3–20.e6 [quiz: 21].

15. Molina-Infante J, Bredenoord AJ, Cheng E, et al. Proton pump inhibitorresponsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. Gut 2016;65(3):524–31.

16. Dellon ES, Liacouras CA, Molina-Infante J, et al. Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference. Gastroenterology 2018;155(4):1022–33.e10.

17. DeBrosse CW, Case JW, Putnam PE, et al. Quantity and distribution of eosinophils in the gastrointestinal tract of children. Pediatr Dev Pathol 2006;9(3):210–8.

18. Lwin T, Melton SD, Genta RM. Eosinophilic gastritis: histopathological characterization and quantification of the normal gastric eosinophil content. Mod Pathol 2011;24(4):556–63.

19. Khoury P, Akuthota P, Ackerman SJ, et al. Revisiting the NIH taskforce on the research needs of eosinophil-associated diseases (RE-TREAD). J Leukoc Biol 2018;104(1):69–83.

20. O’Connell EM, Nutman TB. Eosinophilia in infectious diseases. Immunol Allergy Clin North Am 2015;35(3):493–522.

21. Chou A, Serpa JA. Eosinophilia in patients infected with human immunodeficiency virus. Curr Hiv/AIDS Rep 2015;12(3):313–6.

22. Al Mohajer M, Villarreal-Williams E, Andrade RA, et al. Eosinophilia and associated factors in a large cohort of patients infected with human immunodeficiency virus. South Med J 2014;107(9):554–8.

23. Flores M, Merino-Angulo J, Tanago JG, et al. Late generalized tuberculosis and eosinophilia. Arch Intern Med 1983;143(1):182. Approach to Patients with Eosinophilia 11

24. Vijayan VK, Reetha AM, Jawahar MS, et al. Pulmonary eosinophilia in pulmonary tuberculosis. Chest 1992;101(6):1708–9.

25. Driss V, Legrand F, Hermann E, et al. TLR2-dependent eosinophil interactions with mycobacteria: role of alpha-defensins. Blood 2009;113(14):3235–44.

26. Pfeffer PE, Hopkins S, Cropley I, et al. An association between pulmonary Mycobacterium avium-intracellulare complex infections and biomarkers of Th2-type inflammation. Respir Res 2017;18(1):93.

27. Herrick JA, Legrand F, Gounoue R, et al. Posttreatment reactions after singledose diethylcarbamazine or ivermectin in subjects with loa loa infection. Clin Infect Dis 2017;64(8):1017–25.

28. Rajamanickam A, Munisankar S, Bhootra Y, et al. Elevated systemic levels of eosinophil, neutrophil, and mast cell granular proteins in strongyloides stercoralis infection that diminish following treatment. Front Immunol 2018;9:207.

29. Nutman TB, Miller KD, Mulligan M, et al. Loa loa infection in temporary residents of endemic regions: recognition of a hyperresponsive syndrome with characteristic clinical manifestations. J Infect Dis 1986;154(1):10–8.

30. Thaden J, Cassar A, Vaa B, et al. Eosinophilic endocarditis and Strongyloides stercoralis. Am J Cardiol 2013;112(3):461–2.

31. Romagosa R, Kapoor S, Sanders J, et al. Inpatient adverse cutaneous drug eruptions and eosinophilia. Arch Dermatol 2001;137(4):511–2.

32. Kuruvilla M, Khan DA. Eosinophilic drug allergy. Clin Rev Allergy Immunol 2016; 50(2):228–39.

33. Ramı´rez E, Medrano-Casique N, Tong HY, et al. Eosinophilic drug reactions detected by a prospective pharmacovigilance programme in a tertiary hospital. Br J Clin Pharmacol 2017;83(2):400–15.

34. Ogawa K, Morito H, Hasegawa A, et al. Elevated serum thymus and activationregulated chemokine (TARC/CCL17) relates to reactivation of human herpesvirus 6 in drug reaction with eosinophilia and systemic symptoms (DRESS)/druginduced hypersensitivity syndrome (DIHS). Br J Dermatol 2014;171(2):425–7.